Generic Name and Formulations:
Amphotericin B lipid complex 5mg/mL; susp for IV infusion after dilution; preservative-free.
Sigma-Tau Pharmaceuticals, Inc.
Indications for ABELCET:
Invasive fungal infections in patients who are refractory to, or intolerant of, conventional amphotericin B therapy.
Adults and Children:
5mg/kg daily as a single IV infusion, at a rate of 2.5mg/kg per hour. Renal impairment: reduce dose.
Be fully familiar with the use of this product. Administer under close supervision; cardiopulmonary resuscitation facilities should be available. Monitor CBC, serum creatinine, liver function, serum electrolytes (esp. magnesium and potassium). Pregnancy (Cat.B). Nursing mothers: not recommended.
Monitor other drugs; see literature. Caution with antineoplastics, corticosteroids, ACTH, cyclosporine, digitalis glycosides, flucytosine, imidazoles, nephrotoxic drugs, skeletal muscle relaxants, zidovudine. Concurrent leukocyte transfusion: not recommended.
Infusion reactions (1–2 hrs post-infusion, e.g., transient chills/fever, rarely: bronchospasm, hypotension, arrhythmias, shock), nephrotoxicity, hepatotoxicity, anaphylaxis, respiratory/cardiac/neurological disorders, malaise, tinnitus, visual impairment, hearing loss, diarrhea; others: see literature.
Single-use vials (50mg, 100mg)—1 (w. filter needle)
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D